| Suppression, subversion and escape: the role of regulatory T cells in cancer progression. | |
| | |
MedLine Citation:
|
PMID: 23199321 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Regulatory T cells (T(regs) ) are crucial in mediating immune homeostasis and promoting the establishment and maintenance of peripheral tolerance. However, in the context of cancer their role is more complex, and they are thought to contribute to the progress of many tumours. As cancer cells express both self- and tumour-associated antigens, T(regs) are key to dampening effector cell responses, and therefore represent one of the main obstacles to effective anti-tumour responses. Suppression mechanisms employed by T(regs) are thought to contribute significantly to the failure of current therapies that rely on induction or potentiation of anti-tumour responses. This review will focus on the current evidence supporting the central role of T(regs) in establishing tumour-specific tolerance and promoting cancer escape. We outline the mechanisms underlying their suppressive function and discuss the potential routes of T(regs) accumulation within the tumour, including enhanced recruitment, in-situ or local proliferation, and de-novo differentiation. In addition, we review some of the cancer treatment strategies that act, at least in part, to eliminate or interfere with the function of T(regs) . The role of T(regs) is being recognized increasingly in cancer, and controlling the function of these suppressive cells in the tumour microenvironment without compromising peripheral tolerance represents a significant challenge for cancer therapies. |
| | |
Authors:
|
K Oleinika; R J Nibbs; G J Graham; A R Fraser |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Clinical and experimental immunology Volume: 171 ISSN: 1365-2249 ISO Abbreviation: Clin. Exp. Immunol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2012-12-03 Completed Date: 2013-02-19 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0057202 Medline TA: Clin Exp Immunol Country: England |
Other Details:
|
Languages: eng Pagination: 36-45 Citation Subset: IM |
Copyright Information:
|
© 2012 British Society for Immunology. |
Affiliation:
|
Chemokine Research Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / therapeutic use Disease Progression Humans Immune Tolerance / drug effects, immunology* Mice Neoplasms / drug therapy, immunology* Prognosis T-Lymphocytes, Regulatory / drug effects, immunology* Tumor Escape / drug effects, immunology* Tumor Microenvironment / immunology |
| Grant Support | |
ID/Acronym/Agency:
|
//Medical Research Council |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of stromal cells in the persistence of chronic inflammation.
Next Document: Insulin promotes T cell recovery in a murine model of autoimmune myocarditis.